+

WO2011008298A2 - Nouvelles formes pharmaceutiques de l’axomadol - Google Patents

Nouvelles formes pharmaceutiques de l’axomadol Download PDF

Info

Publication number
WO2011008298A2
WO2011008298A2 PCT/US2010/002011 US2010002011W WO2011008298A2 WO 2011008298 A2 WO2011008298 A2 WO 2011008298A2 US 2010002011 W US2010002011 W US 2010002011W WO 2011008298 A2 WO2011008298 A2 WO 2011008298A2
Authority
WO
WIPO (PCT)
Prior art keywords
axomadol
released
hours
dosage form
pharmaceutically acceptable
Prior art date
Application number
PCT/US2010/002011
Other languages
English (en)
Other versions
WO2011008298A3 (fr
Inventor
Ramesh Sesha
Original Assignee
Nectid, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nectid, Inc. filed Critical Nectid, Inc.
Publication of WO2011008298A2 publication Critical patent/WO2011008298A2/fr
Publication of WO2011008298A3 publication Critical patent/WO2011008298A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms

Definitions

  • the invention is related to a slow release axomadol dosage form and to a method of using such dosage forms. It is also related to combinations of axomadol with an additional active agent such as acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor that are useful for treating a therapeutic disorder in a mammal.
  • an additional active agent such as acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Re
  • Axomadol (6-Dimethylaminomethyl-l-(3-methoxyphenyl)-cyclohexane-l, 3-diol, with other Names: (1R,3R, 6R)-6-(dimethylaminomethyl)-l-(3-methoxyphenyl)cyclohexane-l,3-diol or
  • Axomadol or axomadol known from EP 0 753 506 Bl or U.S. Pat. No. 5,733,936 is of interest for its therapeutic properties. Axomadol formulations are undergoing clinical trials for treating pain.
  • acetaminophen such as naproxen
  • CENODS such as naproxcinod
  • Opiates such as morphine, tramadol, tapentadol, oxycodone etc
  • Antiepileptics such as pregabalin
  • NMDA N-methyl-D-aspartic acid Receptor antagonists like memantine and SNRIs such as duloxetine etc.
  • axomadol dosage forms and combinations of axomadol with other classes of therapeutic drugs such as an acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor etc so that they could be used as longer acting drugs for treating a disorder, especially pains such as fibromyalgia, arthritis and diabetes neuropathy, depression or neurodegenerative disorders.
  • other classes of therapeutic drugs such as an acetaminophen, an NSAID, an Opioid, an Antiepileptic, a No
  • Slow release pharmaceutical dosage forms are well known and provide distinct advantages for delivery of drugs which act optimally at certain levels of plasma concentration over extended periods of time. These are particularly suited for chronic conditions such as neurodegenerative disorders, metabolic diseases, pain and pain related conditions by providing drugs in a sustained released manner that only requires administration either once or twice daily instead of every four to eighteen hours as may be indicated for a particular drug.
  • U.S. Pat 7,410,965 provides a delayed release pharmaceutical formulation containing l-dimethylamino-3-(3- methoxyphenyl)-2-methylpentan-3-ol or a pharmaceutically acceptable salt thereof in a matrix.
  • acetaminophen and tramadol have been described, for example, in U.S. Pat. No. 7,374,781 and U.S. Patent Publication No. US2003/0092724 Al.
  • U.S Pat. App. No. 6,558,701 describes a combination of tramadol and diclofenac.
  • U.S. Pat. No. 20090130183 describes a sustained release formation of tramadol and acetaminophen and U.S. Pat. No. 20100015222 discloses a dosage form of acetaminophen and an opioid for delivery of the drugs to the upper gastrointestinal tract ("GI") of a mammal for an extended period of time.
  • GI gastrointestinal tract
  • a dosage form comprising a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient, and at least one second active agent
  • the said second active agent is selected from a group consisting of acetaminophen, an NSAK), an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor, for treating a patient in need thereof wherein the dosage form is suitable for once or twice daily oral administration.
  • the prior art does not disclose a method of treating a mammal comprising administration of slow release dosage forms of axomadol and the combinations of axomadol and at least one second active agent, wherein the said second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl- D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor.
  • the said second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an Antiepileptic,
  • this invention discloses a slow release dosage form, comprising a therapeutically effective amount of at least one form of axomadol, and at least one pharmaceutically acceptable excipient, suitable for once or twice daily oral administration.
  • the invention further discloses a method of treating a disorder in a mammal with a slow release dosage form comprising a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient, wherein the said dosage form is suitable for once daily or twice daily administration.
  • this invention further discloses a pharmaceutical dosage form comprising a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient and at least one second active agent useful for treating a mammal, wherein the said second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor for treating a disorder in a mammal.
  • the said second active agent is selected from a group consisting of acetaminophen, an
  • the invention discloses a method of treating mammal by administering to a mammal in need thereof, a dosage form comprising a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient and at least one second active agent useful for treating a mammal, wherein the said second active agent is selected from a group consisting of acetaminophen, an NSAED, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRT), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a FIT Agonist and a Proton Pump Inhibitor.
  • the invention also provides such combinations wherein at least one of the active agent is
  • the present invention provides a slow release dosage form comprising a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient, wherein the said dosage form is suitable for once daily or twice daily administration.
  • the present invention provides a method of treating pain, by administering a dosage form comprising, a therapeutically effective amount of at least one form axomadol and at least one
  • the said dosage form is suitable for once daily or twice daily administration.
  • a slow release dosage form comprising at least one form of axomadol and at least one pharmaceutically acceptable excipient, wherein the said dosage form is suitable for once or twice daily oral administration and provides equivalent clinical effect to an immediate release form of same dosage.
  • the present invention provides a method of treating pain, by administering a slow release dosage form comprising at least one form of axomadol and at least one pharmaceutically acceptable excipient, wherein the said dosage form is suitable for once or twice daily oral administration and provides equivalent clinical effect to an immediate release form of same dosage.
  • the present invention provides a pharmaceutical dosage form comprising a therapeutically effective amount of at least one form of axomadol, at least one pharmaceutically acceptable excipient and at least one second active agent, wherein the second active agent is selected from a group consisting acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor.
  • the second active agent is selected from a group consisting acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinep
  • the present invention provides a method of treating a disorder, by administering a dosage form comprising a therapeutically effective amount of at least one form of axomadol, at least one
  • the second active agent is selected from a group consisting acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo- oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor.
  • the second active agent is selected from a group consisting acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo- oxygenase-(COX)-inhibiting
  • the present invention provides a pharmaceutical dosage form comprising a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient and at least one second active agent, wherein the second active agent is selected from a group consisting acetaminophen, an NSAID, an Opioid, an antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor,
  • the second active agent is selected from a group consisting acetaminophen, an NSAID, an Opioid, an antiepileptic, a Norepinep
  • the present invention provides a pharmaceutical dosage form comprising a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient and at least one second active agent, wherein the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor, wherein at least one of the active agents is in slow release form.
  • the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opio
  • the present invention is related in part to a therapeutic dosage forms administered orally, via implant, transdermal Iy, parenterally, sublingually, rectally, buccally, topically, via inhalation, etc.
  • axomadol can be administered separately from the second analgesic, as set forth in more detail below.
  • the invention provides a dosage form comprising a therapeutically effective amount of at least one form of axomadol, at least one pharmaceutically acceptable excipient and at least one second active agent, wherein the second active agent is selected from a group consisting acetaminophen, an NSAlD, an Opioid, an antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D- aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor that allows the use of lower doses of the second active agent or the, or lower doses of both drugs than would normally be required when either drug is used alone. By using lower amounts of either or both drugs, the side effects
  • the invention further relates to the use of a pharmaceutical combination of at least one form of axomadol, at least one pharmaceutically acceptable excipient, at least one second active agent, wherein the dosage form is suitable for once daily or twice daily administration.
  • the invention further relates to the use of a pharmaceutical combination of at least one form of axomadol together with an antiepileptic to provide effective treatment of pain.
  • the invention further relates to the use of a pharmaceutical combination of at least one form of axomadol together with 5-HT agonist to provide treatment of head ache including migraine.
  • the invention further relates to the use of a pharmaceutical combination of at least one form of axomadol together with an NMDA antagonist to provide treatment of a disorder such as pain, neurodegenerative disorder or metabolic disease.
  • the invention further relates to the use of and at least one form Axomadol and at least one second active agent, wherein the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl- D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor, for the treatment of a disorder.
  • the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor,
  • FIGURE 1 is the dissolution profile of a slow release Axomadol dosage form according to
  • FIGURE 2 is the dissolution profile of a slow release Axomadol dosage form according to
  • FIGURE 3 is the dissolution profile of a slow release Axomadol dosage form according to
  • FIGURE 4 is the dissolution profile of a slow release Axomadol dosage form according to
  • FIGURE 5 is the dissolution profile of a slow release Axomadol dosage form according to
  • Figure 6 shows the VAS Pain scores for Slow Release Axomadol (Example 1) and Immediate
  • FIGURE 7 shows the VAS Pain Score for the treatment involving Axomadol (Reference
  • Example 1 Pregabalin, Fixed Dose Combination of Axomadol and Pregabalin (Example 38) and
  • axomadol as used herein is defined to mean at least one form of axomadol chosen from axomadol salt, the individually optically active enantiomers of axomadol, such as for example, (+) or (-) forms of axomadol, racemic mixtures thereof, active metabolites, pharmaceutically acceptable salts thereof, such as for example, acid addition or base addition salts of axomadol.
  • Acids commonly employed to form acid addition salts are inorganic acids, such as for example, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, and the like, and organic acids such as p-toluenesulfonic, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
  • examples of such pharmaceutically acceptable salts are the sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate,
  • Base addition salts include those derived from inorganic bases, such as for example, ammonium or alkali or alkaline earth metal hydroxides, carbonates, bicarbonates, and the like.
  • Such bases useful in preparing the salts of this invention thus include sodium hydroxide, potassium hydroxide, ammonium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
  • Active Agent means axomadol, acetaminophen, an NSAID, an Opioid, an antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D- aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump
  • administration or ingestion means administration of dose of a formulation containing an active ingredient administered to a patient or subject.
  • Alcoholcholinesterase inhibitor as used in this inventions means an entity that inhibits cholinesterase enzyme and they include, but not limited to, Metrifonate, Physostigmine,
  • Neostigmine Pyridostigmine, Ambenonium, Demarcarium, Rivastigmine, Galantamine, Donepezil,
  • analgesic means to include any drug used to relieve pain including paracetamol (acetaminophen), the non-steroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, oxycodone, etc synthetic drugs with narcotic properties such as tramadol and tapentadol, CINODS such as naproxcinod, SNRIs like duloxetine, GABA analogues like pregabalin , gabapentin and various others classes of drugs not normally considered analgesics are used to treat neuropathic pain syndromes; these include tricyclic antidepressants and anticonvulsants.
  • NSAIDs non-steroidal anti-inflammatory drugs
  • Antiepileptic or Antiepileptics refers to class of compounds also referred to as anticonvulsants and they include , but not limited to, aminobutyric acid, beclamide, barbexaclone, brivaracetam, clonazepam, carbamazepine, ethotoin, ethadione, ethosuximide, eslicarbazepine, felbamate, fosphenytoin, gabapentin, lamotrigine, levetiracetam, lacosamide, mephenytoin, methylphenobarbital, metharbital, mesuximide, oxcarbazepine, phenytoin, phenobarbital, primidone, paramethadione, phenacemide, pheneturide, phensuximide, pregabalin, progabide rufinamide, selectracetam, stiripentol, sul
  • area under curve or AUC refers to the area under the plasma
  • bioequivalence or bioequivalent is defined as the absence of a significant difference in the rate and extent to which the active ingredient or active moiety in pharmaceutical equivalents or pharmaceutical alternatives becomes available at the site of drug action when administered at the same molar dose under similar conditions in an appropriately designed study.
  • the bioavailability (AUC) of axomadol as determined by standard methods is about 80 to about 125% of the second orally administrable dosage form comprising the same dose of at least one form axomadol and that there is a about 90% or greater probability that the maximum blood plasma concentration (C m3x ) of at least one form axomadol as measured by standard methods is about 80 to about 125% of the second orally administrable dosage form. It means the bioequivalence or bioequivalent under FDA guidelines.
  • binding agent refers to any conventionally known pharmaceutically acceptable binder such as polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methylcellulose, ethylcellulose, polymethacrylate, polyvinylalcohol, waxes and the like. Mixtures of the aforementioned binding agents may also be used.
  • the preferred binding agents are water soluble materials such as polyvinyl pyrrolidone having a weight average molecular weight of 25,000 to 3,000,000.
  • the binding agent may comprise approximately about 0 to about 40% of the total weight of the core and preferably about 3% to about 15% of the total weight of the core. In one embodiment, the use of a binding agent in the core is optional.
  • Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator or “CINODs” as used herein have a nitric oxide (NO)-releasing group and are also designated No-NSAIDs and includes naproxcinod.
  • clinical effect as used herein as clinical efficacy with respect to pain experienced by study subjects measured using a suitable scale, for example; in treating pain, clinical effect is measured by WOMAC global score, Likert-scale, or VAS score.
  • C m3x as used herein means the mean maximum plasma concentration of at least one form axomadol.
  • controlled release as used herein is defined to mean a substantially gradual rate of release of the drug.
  • the rate of release of the drug is controlled by features of the dosage form and/or in combination with physiologic or environmental conditions rather than by physiologic or environmental conditions alone.
  • controlled-release dosage forms or dosage forms which exhibit a "controlled- release" of at least one form axomadol as used herein is defined to mean dosage forms administered once daily that release drug at a relatively constant rate and provide plasma concentrations of the active drug that remain substantially invariant with time within the therapeutic range of the active drug over about a 12 to 24-hour period.
  • the term “candidate for sustained release” encompasses all the characteristics of a drug which make it a candidate for formulating it into an extended release fashion like a short elimination half life and consequent dosing of more than once a day, a single dose product given in an extended fashion to achieve better clinical results and avoid side effects associated with an immediate release etc.
  • Delayed-release dosage forms or dosage forms which exhibit a delayed-release of the drug.
  • a dosage form as used herein is defined to mean a solid oral pharmaceutical preparation or system in which doses of medicine or active drug are included.
  • a dosage form will desirably comprise, for example, at least one slow release dosage form including various slow release forms such as, osmosis controlled-release dosage form, erosion controlled-release dosage form, dissolution controlled-release dosage form, diffusion controlled-release dosage form, controlled-release matrix core, controlled-release matrix core coated with at least one release-slowing coat, enteric coated dosage form, one sustained dosage, dosage form surrounded by at least one delayed-release coat, capsules, minitablets, caplets, uncoated microparticles, microparticles coated with release-slowing coat, microparticles coated with delayed-release coat or any combination thereof.
  • dosage forms or dosage forms which exhibit an “enhanced absorption” of the drug as used herein is defined to mean dosage forms that when exposed to like conditions, will show higher release and/or higher absorption of the drug as compared to other dosage forms with the same or higher amount of drug.
  • the term "effective amount” as used herein means a dosage which is sufficient in order for the treatment of the patient to be effective compared with no treatment.
  • extended release material refers to one or more hydrophilic polymers and/or one or more hydrophobic polymers and/or one or more other type hydrophobic materials, such as, for example, one or more waxes, fatty alcohols and/or fatty acid esters.
  • extended-release dosage forms or dosage forms which exhibit an "extended release” of drug as used herein is defined to mean dosage forms administered once daily that release drug slowly, so that plasma concentrations of the drug are maintained at a therapeutic level for an extended period of time such that the sustained-release dosage form provides therapeutic benefit over a 12-24-hour period.
  • hydrophilic polymers include, but are not limited to hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium, carboxymethyl- cellulose, carboxymethylcellulose calcium, ammonium alginate, sodium alginate, potassium alginate, calcium alginate, propylene glycol alginate, alginic acid, polyvinylalcohol, povidone, carbomer, potassium pectate, potassium pectinate, etc
  • hydrophobic polymers include, but are not limited, to ethyl cellulose, hydroxyethylcellulose, ammonio methacrylate copolymer (Eudragit RLTM or Eudragit
  • immediate release coat is defined to mean a coat, which has substantially or appreciably no influence on the rate of release of axomadol from the dosage form in-vitro or in-vivo.
  • the excipients comprising the immediate release coat have no substantial slow release, swelling, erosion, dissolution, or erosion and swelling properties, which means that the composition of the coat has no substantial influence on the rate of release of the axomadol.
  • the term "medicament” as used herein means a dosage form suitable for administration of the pharmaceutically active compound to a patient.
  • C max mean maximum plasma concentration
  • mean plasma concentration means the arithmetic mean blood plasma concentration of at least one form axomadol.
  • modified-release dosage forms or dosage forms which exhibit drug release characteristics of time course and/or location are designed to accomplish therapeutic or convenience objectives not offered by an immediate-release dosage forms.
  • Modified-release dosage forms or dosage forms are typically designed to provide a quick increase in the plasma concentration of the drug which remains substantially constant within the therapeutic range of the drug for at least a 12-24-hour period.
  • microparticle as used herein is defined to mean a plurality of drug-containing entities, such as for example microspheres, spherical particles, microcapsules, particles, microparticles, granules, spheroids, beads, pellets, or spherules.
  • NMDA antagonists or NMDA Antagonist as used herein means inhibitors or modulators of NMDA (N-methyl-D-aspartic acid) receptors including Amantadine, Dextromethorphan,
  • NSAID Nonsteroidal anti-inflammatory drugs such as Ibuprofen,
  • Naproxen Fenoprofen, Ketoprofen, Flurbiprofen, Oxaprozin, Indomethacin, Sulindac, Etodolac,
  • Diclofenac Diclofenac, Piroxicam, Meloxicam, Tenoxicam, Droxicam, Lornoxicam, Isoxicam, Mefenamic acid, Meclofenamic acid, Flufenamic acid, Tolfenamic acid, Celecoxib, Rofecoxib, Valdecoxib, Parecoxib, Lumiracoxib, Etoricoxib etc.
  • Serotonin Norepinephrine Reuptake inhibitors means the class of antidepressant used in the treatment of clinical depression and other affective disorders including
  • Venlafaxine duloxetine, milnacipran and desvenlafaxine etc.
  • Norepinephrine Reuptake inhibitors (NRI, NERJ) or adrenergic reuptake inhibitor (ART) means the class of drug which acts as a reuptake inhibitor for the neurotransmitters
  • norepinephrine norepinephrine
  • epinephrine epinephrine
  • norepinephrine transporter include, but limited to, Atomoxetine/Tomoxetine, Mazindol, Reboxetine, and
  • optimal us used herein means an amount which is the optimal dosage for that compound when used in single-compound therapy.
  • opioid agonists useful in the present invention include, but are not limited to, alfentanil, allylprodine, alphaprodine, anileridine, benzylmorphine, bezitramide, buprenorphine, butorphanol, clonitazene, codeine, desomorphine, dextromoramide, dezocine, diampromide, diamorphone, dihydrocodeine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene, ethylmorphine, etonitazene, faxeladol, fent
  • osmotic dosage form "osmotic delivery device”, as used herein is defined to mean dosage forms which forcibly dispense the drug all or in partially by pressure created by osmosis or diffusion of fluid into a core which forces the drug to be dispensed from the osmotic dosage form.
  • prevention of a disease is defined as the management and care of an individual at risk of developing the disease prior to the clinical onset of the disease.
  • the piupose of prevention is to combat the development of the disease, condition or disorder, and includes the administration of the active compounds to prevent or delay the onset of the symptoms or complications and to prevent or delay the development of related diseases, conditions or disorders.
  • pain and pain related conditions is defined as any pain due to a medical conditions including but not limited to neuropathic pain, osteoarthritis, rheumatoid arthritis, fibromyalgia, and back, musculoskeletal pain, Ankylosing spondylitis, juvenile rheumatoid arthritis, migraines, dental pain, abdominal pains, ischemic pain, postoperative pain or because of an anesthetic or surgical contrition.
  • pharmaceutically acceptable derivative means various pharmaceutical equivalent isomers, enantiomers, salts, hydrates, polymorphs, esters etc of at least one form axomadol.
  • Proton Pump Inhibitor or PPI means any active agent that blocks hydrogen/potassium adenosine triphosphatase enzyme system (the H+/K+ ATPase,) of the gastric parietal cell including Omeprazole, Lansoprazole, Esomeprazole, Pantoprazole and Rabeprazole
  • 5-HTagonists as used herein means drugs that act on 5-HT receptor including sumatriptan, rizatriptan, zolmitriptan, almotriptan and frovatriptan.
  • second active agent means an active agent selected from a group consisting acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor.
  • SNRI Serotonin Norepinephrine reuptake inhibitor
  • COX Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator
  • NMDA N-methyl-D-aspartic acid
  • sub-optimal or sub-therapeutic means an amount which is below the optimal dosage for that compound when used in single-compound therapy.
  • slow-release here applies to any release formulation that is other than an immediate release wherein the release of the active ingredient is slow in nature. This includes various terms used interchangeably in the pharmaceutical context like extended release, delayed release, sustained release, controlled release, timed release, specific release, prolonged release and targeted release etc.
  • sustained-release dosage forms or dosage forms which exhibit a "sustained- release” of the drug as used herein is defined to mean dosage forms administered once daily that provide a release of the drug sufficient to provide a therapeutic dose after administration, and then a gradual release over an extended period of time such that the sustained-release dosage form provides therapeutic benefit over a 12 to 24-hour period.
  • treatment of a disease means the management and care of a patient having developed the disease, condition or disorder.
  • the purpose of treatment is to combat the disease, condition or disorder.
  • Treatment includes the administration of the active compounds to eliminate or control the disease, condition or disorder as well as to alleviate the symptoms or complications associated with the disease, condition or disorder.
  • freeze daily oral pharmaceutical composition as used herein is defined as any axomadol formulation administered two times a day to a patient in need of.
  • terapéuticaally effective amount means an amount that elicits a biological response in a mammal including the suboptimal amount.
  • T 1113x as used herein means a mean time to maximum plasma concentration of at least one form of axomadol.
  • the oral solid dosage form includes a sustained release carrier which causes the sustained release of the second active agent, or both the second active agent and at least one form of axomadol when the dosage form contacts gastrointestinal fluid.
  • the sustained release dosage form may comprise a plurality of substrates which include the drugs.
  • the substrates may comprise matrix spheroids or may comprise inert pharmaceutically acceptable beads which are coated with the drugs.
  • the coated beads are then preferably over coated with a sustained release coating comprising the sustained release carrier.
  • the matrix spheroid may include the sustained release carrier in the matrix itself; or the matrix may comprise a normal release matrix containing the drugs, the matrix having a coating applied thereon which comprises the sustained release carrier.
  • the oral solid dosage form comprises a tablet core containing the drugs within a normal release matrix, with the tablet core being coated with a sustained release coating comprising the sustained release carrier.
  • the tablet contains the drugs within a sustained release matrix comprising the sustained release carrier.
  • the tablet contains the opioid analgesic within a sustained release matrix and at least one form of axomadol coated into the tablet as an immediate release layer.
  • the present invention discloses a slow release pharmaceutical composition
  • axomadol and at least one pharmaceutically acceptable excipient
  • the composition preferably contains a therapeutically effective amount of axomadol or a pharmaceutically acceptable salt thereof, wherein the axomadol is suitably in the range of from 5 to 2000 mg, especially about 250, 500,
  • Granules, spheroids, pellets, multiparticulates, capsules, patches tablets, sachets, controlled release suspensions, or in any other suitable dosage form incorporating such granules, spheroids, pellets or multiparticulates are also a part of the present invention.
  • the one or more of active ingredient in the composition according to the present invention may suitably be incorporated in a matrix.
  • a matrix may be any matrix, known to a person skilled the art, that affords slow release axomadol over at least a twelve hour period and preferably that affords in-vitro dissolution rates and in vivo absorption rates of axomadol within the therapeutically effective ranges.
  • the formulation according to the present invention may preferably use a slow release matrix.
  • normal release matrices having a coating which provides for slow release of the axomadol may be used.
  • This may be any matrix that affords axomadol released over at least a twelve hour period and preferably that affords in-vitro dissolution rates and in vivo absorption rates of axomadol within the ranges specified above.
  • the matrix is a controlled release matrix.
  • normal release matrices having a coating which provides for controlled release of the active ingredient may be used.
  • the slow release matrix employed in the composition of this invention may also contain other pharmaceutically acceptable ingredients which are conventional in the pharmaceutical art such as diluents, lubricants, binders, granulating aids, colorants, flavourants, surfactants, pH adjusters, anti- adherents and glidants, e.g. dibutyl sebacate, ammonium hydroxide, oleic acid and colloidal silica.
  • diluent e.g. microcrystalline cellulose, lactose and dicalcium phosphate may be used to prepare this combination.
  • Suitable lubricants are e.g. magnesium stearate and sodium stearyl fumarate.
  • Suitable binding agents are e.g. hydroxypropyl methyl cellulose, polyvidone and methyl cellulose.
  • Suitable disintegrating agents are starch, sodium starch glycolate, and crospovidone and croscarmellose sodium.
  • the slow release matrix employed in the composition of this invention may also contain other pharmaceutically acceptable ingredients which are conventional in the pharmaceutical art such as diluents, lubricants, binders, granulating aids, colorants, flavourants, surfactants, pH adjusters, anti- adherents and glidants, e.g. dibutyl sebacate, ammonium hydroxide, oleic acid and colloidal silica.
  • diluent e.g. microcrystalline cellulose, lactose and dicalcium phosphate may be used to prepare this combination.
  • Suitable lubricants are e.g. magnesium stearate and sodium stearyl fumarate.
  • Suitable binding agents are e.g. hydroxypropyl methyl cellulose, polyvidone and methyl cellulose.
  • Suitable disintegrating agents are starch, sodium starch glycolate, and crospovidone and croscarmellose sodium.
  • Slow release matrix of present invention includes materials such as Polyalkylene glycols, Long Chain Hydrocarbons and Hydrophilic or hydrophobic polymers, such as gums, cellulose ethers, acrylic resins and protein derived materials. Of these polymers, the cellulose ethers, especially alkyl celluloses are preferred.
  • the preparation may conveniently contain between 1% and 80% (by weight) of one or more hydrophilic or hydrophobic polymers. Still further Digestible, long chain (C.8 -C50), substituted or un-substituted hydrocarbons, such as fatty acids, fatty alcohols, glyceryl esters of fatty acids, mineral and vegetable oils and waxes, Of these long chain hydrocarbon materials, fatty (aliphatic) alcohols are preferred.
  • the preparation may conveniently contain up to 60% (by weight) of at least one digestible, long chain hydrocarbon.
  • Surface actives that are suitable for this invention are Poloxamer 188.RTM, polysorbate 80 and sodium lauryl sulfate.
  • the suitable flow aids for this invention are talc colloidal anhydrous silica.
  • the suitable water soluble polymers that may be used to prepare the matrix are PEG with molecular weights in the range 1000 to 6000.
  • the combination comprising the slow release axomadol according to the invention may conveniently be film coated using any film coating material conventional in the pharmaceutical art but preferably an aqueous film coating is used.
  • the composition as per this invention may comprise a normal release matrix having a slow release coating.
  • the combination comprises film coated spheroids containing the active ingredient and a spheronising agent.
  • the spheronising agent may be any suitable pharmaceutically acceptable material which may be spheronised together with the active ingredient to form spheroids.
  • a preferred spheronising agent as per this invention is microcrystalline cellulose.
  • the microcrystalline cellulose used may suitably be, for example, Avicel PH 101 or Avicel PH 102 (Trade Marks, FMC Corporation).
  • the spheroids may optionally contain other pharmaceutically acceptable ingredients conventional in the pharmaceutical art such as binders, bulking agents and colorants. Suitable binders may include water soluble polymers, water soluble hydroxyalkyl celluloses such as
  • hydroxypropylcellulose or water insoluble polymers such as acrylic polymers or copolymers for example ethylcellulose.
  • Suitable bulking agents include lactose.
  • Slow release form according to this invention includes osmotic dosage forms with or without passageway or a pore.
  • the spheroids are coated with a material which permits release of the active ingredient at a slow rate in an aqueous medium.
  • Suitable slow release coating materials that may be used in this invention include water insoluble waxes and polymers such as polymethylacrylates (for example Eudragit polymers) or water insoluble celluloses, particularly ethylcellulose.
  • water soluble polymers such as polyvinylpyrrolidone or water soluble celluloses such as hydroxypropylmethylcellulose or hydroxypropylcellulose may be included.
  • other water soluble agents such as polysorbate 80 may be added.
  • a flux-enhancing agent can also be included in the membrane or slow release coating can include one of the above-described polymers.
  • the flux enhancing agent can increase the volume of fluid imbibed into the core to enable the dosage form to dispense substantially all of the axomadol through the passage and/or the porous membrane.
  • the flux-enhancing agent can be a water-soluble material or an enteric material.
  • Examples of the preferred materials that are useful as flux enhancers include but not limited to sodium chloride, potassium chloride, sucrose, sorbitol, mannitol, polyethylene glycols (PEG), propylene glycol, hydroxypropyl cellulose, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose phthalate, cellulose acetate phthalate, polyvinyl alcohols, methacrylic acid copolymers, poloxamers (such as LUTROL F68, LUTROL F127, LUTROL F108 which are commercially available from BASF) and mixtures thereof.
  • a preferred flux-enhancer used in this invention is PEG 400.
  • a commonly known excipient such as a plasticizer may also be used for preparing the membrane or slow release coating
  • plasticizers include but not limited to adipate, azelate, enzoate, citrate, stearate, isoebucate, sebacate, triethyl citrate, tri-n-butyl citrate, acetyl tri-n-butyl citrate, citric acid esters, and all those described in the Encyclopedia of Polymer Science and Technology, Vol. 10 (1969), published by John Wiley & Sons.
  • the preferred plasticizers are triacetin, acetylated monoglyceride, grape seed oil, olive oil, sesame oil, acetyltributylcitrate, acetyltriethylcitrate, glycerin sorbitol, diethyloxalate, diethylmalate, diethylfumarate, dibutylsuccinate, diethylmalonate,
  • dioctylphthalate dibutyl sebacate, triethyl citrate, tributyl citrate, glycerol tributyrate and the like.
  • plasticizer typically amounts from about 0 to about 25% are used, and preferably about 2% to about 15% of the plasticizer can be used based upon the total weight of the membrane or sustained release coating.
  • the membrane or slow release coating around the core will comprise from about 1% to about 20% and preferably about 2% to about 10% based upon the total weight of the core and coating.
  • the slow release pharmaceutical composition according to the instant invention may be any suitable slow release pharmaceutical composition according to the instant invention.
  • any film coating material conventional in the pharmaceutical art such as an aqueous film coating.
  • the slow release composition according to the instant invention may comprise a normal release matrix having a slow release coating and preferably the slow release composition comprises film coated spheroids containing the active ingredient and a spheronising agent.
  • the release profile can be modified in a number of ways; 1) loading of the drug will be associated with increased release rates; 2) the use of larger proportions of the water soluble fusible material in the particles or surface active agent in the tabletting formulation will also be associated with a higher release rate of the active ingredient and, 3) by controlling the relative amounts of these ingredients it is possible to adjust the release profile of the axomadol or a salt thereof.
  • particles may be produced according to standard procedures known in the art such as using a Y-Cone or bin-blender, using a suitable size tabletting mould and using conventional tabletting machines.
  • the membrane or sustained release coating surrounding the core can further optionally comprise a passage that will allow for controlled release of the drug from the core in a preferred embodiment.
  • the term passage includes an aperture, orifice, bore, hole, weakened area or a credible element such as a gelatin plug that erodes to form an osmotic passage for the release of the axomadol from the dosage form.
  • the passage used, in accordance with the subject invention are well known and are described in U.S. Pat. Nos. 3,845,770; 3,916,899; 4,034,758; 4,077,407; 4,783,337 and 5,071,607
  • the invention comprises an oral solid dosage form comprising a therapeutically effective amount of a second active agent, wherein the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, a HT Agonist and a Proton Pump Inhibitor, with an amount of a pharmaceutical preparation containing axomadol or pharmaceutically acceptable salt thereof which augments the effect of the second active agent.
  • the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a
  • the pharmaceutical compositions comprising at least one form of axomadol and a second active agent, wherein the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor, set forth herein are administered orally.
  • the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an Antiepileptic, a Norepinephrine Reuptake Inhibitor, a
  • Such oral dosage forms may contain one or both of the drugs in immediate or sustained release form. For ease of administration, it is preferred that the oral dosage form contains both drugs.
  • the oral dosage forms may be in the form of tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, multiparticulate formulations, syrups, elixirs, and the like.
  • compositions comprising at least one form of axomadol and a second active agent, wherein the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D- aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor, set forth herein may alternatively be in the form of microparticles (e.g., microcapsules, microspheres and the like), which may be injected or implanted into a human patient, or other implantable dosage forms known to those skilled in the art of pharmaceutical formulation.
  • the second active agent is
  • Antiepileptic, a Norepinephrine Reuptake Inhibitor, a Serotonin Norepinephrine reuptake inhibitor (SNRI), a Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator, NMDA (N-methyl-D-aspartic acid) Receptor antagonist, an Acetylcholinesterase inhibitor, a HT Agonist and a Proton Pump Inhibitor can be employed in admixtures with conventional excipients, i.e., pharmaceutically acceptable organic or inorganic carrier substances suitable for oral, parenteral, nasal, intravenous, subcutaneous, enteral, or any other suitable mode of administration, known to the art.
  • Suitable pharmaceutically acceptable carriers include but are not limited to water, salt solutions, alcohols, gum arabic, vegetable oils, benzyl alcohols, polyethylene glycols, gelate, carbohydrates such as lactose, amylose or starch, magnesium stearate talc, silicic acid, viscous paraffin, perfume oil, fatty acid monoglycerides and diglycerides, penta erythritol fatty acid esters, hydroxymethylcellulose,
  • the pharmaceutical preparations can be sterilized and if desired mixed with auxiliary agents, e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or aromatic substances and the like. They can also be combined where desired with other active agents, e.g., other analgesic agents.
  • auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or aromatic substances and the like.
  • auxiliary agents e.g., lubricants, preservatives, stabilizers, wetting agents, emulsifiers, salts for influencing osmotic pressure buffers, coloring, flavoring and/or aromatic substances and the like.
  • other active agents e.g., other analgesic agents.
  • particularly suitable are oily or
  • compositions intended for oral use may be prepared according to any method known in the art and such compositions may contain one or more agents selected from the group consisting of inert, non-toxic pharmaceutically excipients which are suitable for the manufacture of tablets.
  • excipients include, for example an inert diluent such as lactose; granulating and disintegrating agents such as cornstarch; binding agents such as starch; and lubricating agents such as magnesium stearate.
  • the tablets may be uncoated or they may be coated by known techniques for elegance or to delay release of the active ingredients.
  • Formulations for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert diluent.
  • Aqueous suspensions contain the above-identified combination of drugs and that mixture has one or more excipients suitable as suspending agents, for example pharmaceutically acceptable synthetic gums such as hydroxypropylmethylcellulose or natural gums.
  • Oily suspensions may be formulated by suspending the above-identified combination of drugs in a vegetable oil or mineral oil.
  • the oily suspensions may contain a thickening agent such as beeswax or cetyl alcohol, syrup, elixir, or the like can be used wherein a sweetened vehicle is employed.
  • Injectable suspensions may also be prepared, in which case appropriate liquid carriers, suspending agents and the like may be employed. It is also possible to freeze-dry the active compounds and use the obtained lyophilized compounds, for example, for the preparation of products for injection.
  • the sustained release dosage form may optionally include a sustained released carrier which is incorporated into a matrix along with axomadol, or which is applied as
  • the sustained release dosage form may include the second active agent in sustained release form and at least one form of axomadol in sustained release form or in immediate release form. At least one form of axomadol may be incorporated into the sustained release matrix along with the second active agent; incorporated into the sustained release coating; incorporated as a separated sustained release layer or immediate release layer; or may be incorporated as a powder, granulation, etc., in a gelatin capsule with the substrates of the present invention. Alternatively, the sustained release dosage form may have at least one form of axomadol in sustained release form and the second active agent in sustained release form or immediate release form.
  • the dosage forms of the present invention may optionally be coated with one or more materials suitable for the regulation of release or for the protection of the formulation.
  • coatings are provided to permit either pH-dependent or pH-independent release, e.g., when exposed to gastrointestinal fluid.
  • a pH-dependent coating serves to release the axomadol in desired areas of the gastro-intestinal (GI) tract, e.g., the stomach or small intestine, such that an absorption profile is provided which is capable of providing at least about twelve hour and preferably up to twenty-four hour analgesia to a patient.
  • GI gastro-intestinal
  • the coating is designed to achieve optimal release regardless of pH-changes in the environmental fluid, e.g., the GI tract.
  • compositions which release a portion of the dose in one desired area of the GI tract, e.g., the stomach, and release the remainder of the dose in another area of the GI tract, e.g., the small intestine.
  • Formulations according to the invention that utilize pH-dependent coatings to obtain formulations may also impart a repeat-action effect whereby unprotected drug is coated over the enteric coat and is released in the stomach, while the remainder, being protected by the enteric coating, is released further down the gastrointestinal tract.
  • Coatings which are pH-dependent may be used in accordance with the present invention include shellac, cellulose acetate phthalate (CAP), polyvinyl acetate phthalate (PVAP), hydroxypropylmethylcellulose phthalate, and methacrylic acid ester copolymers, zein, and the like.
  • CAP cellulose acetate phthalate
  • PVAP polyvinyl acetate phthalate
  • zein methacrylic acid ester copolymers
  • Cellulosic materials and polymers including alkyl celluloses, provide hydrophobic materials well suited for coating the beads according to the invention.
  • one preferred alkyl cellulosic polymer is ethylcellulose, although the artisan will appreciate that other cellulose and/or alkyl cellulose polymers may be readily employed, singly or in any combination, as all or part of a hydrophobic coating according to the invention.
  • the hydrophobic material comprising the controlled release coating is a pharmaceutically acceptable acrylic polymer, including but not limited to acrylic acid and methacrylic acid copolymers, methyl methacrylate copolymers, ethoxyethyl
  • methacrylates cyan ethyl methacrylate, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkyl amide copolymer, poly(methyl methacrylate), polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, amino alkyl methacrylate copolymer, poly(methacrylic acid anhydride), and glycidyl methacrylate copolymers.
  • the inclusion of an effective amount of a plasticizer in the aqueous dispersion of hydrophobic material will further improve the physical properties of the sustained release coating.
  • a plasticizer into an ethylcellulose coating containing sustained release coating before using the same as a coating material.
  • the amount of plasticizer included in a coating solution is based on the concentration of the film-former, e.g., most often from about 1 to about 50 percent by weight of the film-former.
  • plasticizers for ethylcellulose include water insoluble plasticizers such as dibutyl sebacate, diethyl phthalate, triethyl citrate, tributyl citrate, and triacetin, although it is possible that other water-insoluble plasticizers (such as acetylated monoglycerides, phthalate esters, castor oil, etc.) may be used.
  • Triethyl citrate is an especially preferred plasticizer for the aqueous dispersions of ethyl cellulose of the present invention.
  • the release of the therapeutically active agent from the controlled release formulation of the present invention can be further influenced, i.e., adjusted to a desired rate, by the addition of one or more release-modifying agents, or by providing one or more passageways through the coating.
  • the ratio of hydrophobic material to water soluble material is determined by, among other factors, the release rate required and the solubility characteristics of the materials selected.
  • the release-modifying agents which function as pore-formers may be organic or inorganic, and include materials that can be dissolved, extracted or leached from the coating in the environment of use.
  • the pore-formers may comprise one or more hydrophilic materials such as
  • the sustained release coatings of the present invention can also include erosion-promoting agents such as starch and gums.
  • the sustained release coatings of the present invention can also include materials useful for making micro porous lamina in the environment of use, such as polycarbonates comprised of linear polyesters of carbonic acid in which carbonate groups reoccur in the polymer chain.
  • the release-modifying agent may also comprise a semi-permeable polymer.
  • the controlled release formulation is achieved via a matrix having a controlled release coating as set forth above.
  • the present invention may also utilize a controlled release matrix that affords in-vitro dissolution rates of the opioid within the preferred ranges and that releases the opioid in a pH-dependent or pH-independent manner.
  • the materials suitable for inclusion in a controlled release matrix will depend on the method used to form the matrix.
  • a matrix in addition to the second active agent and at least one form of axomadol may include:
  • Hydrophilic and/or hydrophobic materials such as gums, cellulose ethers, acrylic resins, protein derived materials; the list is not meant to be exclusive, and any pharmaceutically acceptable hydrophobic material or hydrophilic material which is capable of imparting controlled release of the active agent and which melts (or softens to the extent necessary to be extruded) may be used in accordance with the present invention.
  • the invention is directed in part to synergistic combinations of at least one form of axomadol in an amount sufficient to render a therapeutic effect together with a second active agent, such that the therapeutic effect is attained which is greater than that obtained with the dose of second active agent alone.
  • the combination is administered in a single dosage form. In other embodiments, the combination is administered separately, preferably concomitantly.
  • the invention is directed to pharmaceutical formulations comprising at least one form of axomadol in an amount sufficient to render a therapeutic effect together with a therapeutically effective or sub-therapeutic amount of a second active agent.
  • the invention is directed to pharmaceutical formulations comprising at least one form of axomadol in an amount sufficient to render a therapeutic effect together with a therapeutically effective or sub-therapeutic amount of an opioid analgesic selected from the group consisting of morphine, dihydrocodeine, hydromorphone, oxycodone, oxymorphone, salts thereof, and mixtures of any of the foregoing.
  • an opioid analgesic selected from the group consisting of morphine, dihydrocodeine, hydromorphone, oxycodone, oxymorphone, salts thereof, and mixtures of any of the foregoing.
  • the invention is directed to pharmaceutical formulations comprising at least one form of axomadol in an amount sufficient to render a therapeutic effect together with a therapeutically effective or sub-therapeutic amount of a 5-HT agonist.
  • the invention is directed to pharmaceutical formulations comprising at least one form of axomadol in an amount sufficient to render a therapeutic effect together with a therapeutically effective or sub-therapeutic amount of a proton Pump Inhibitor.
  • the invention is directed to pharmaceutical formulations comprising at least one form of axomadol in an amount sufficient to render a therapeutic effect together with a therapeutically effective or sub-therapeutic amount of an Antiepileptic.
  • the invention is directed to pharmaceutical formulations comprising at least one form of axomadol in an amount sufficient to render a therapeutic effect together with a therapeutically effective or sub-therapeutic amount of second active agent selected from the group consisting of Amantadine, Dextromethorphan, Dextrorphan, Dizocilpine (MK-801, Eticyclidine,
  • the invention is directed to pharmaceutical formulations comprising at least one form of axomadol in an amount sufficient to render a therapeutic effect together with a therapeutically effective or sub-therapeutic amount of a second active agent selected from the group consisting of Venlafaxine, Desvenlafaxine, Duloxetine, Milnacipran, Levomilnacipran (F2695),
  • the invention is directed to pharmaceutical formulations comprising at least one form of axomadol in an amount sufficient to render a therapeutic effect together with a therapeutically effective or sub-therapeutic amount of a second active agent selected from the group consisting of Atomoxetine/Tomoxetine, Mazindol, Reboxetine, and Viloxazine (Vivalan).
  • a second active agent selected from the group consisting of Atomoxetine/Tomoxetine, Mazindol, Reboxetine, and Viloxazine (Vivalan).
  • the synergistic combination provides a therapeutic effect which is up to about 30-40 times greater than that obtained with the dose of second active agent alone.
  • the doses of at least one form of axomadol and the second active agent are co-administered orally.
  • the doses of at least one form of axomadol and the second active agent are administered in a single oral dosage form.
  • the doses of at least one form of axomadol and the second active agent are administered in a single oral dosage form, at least one of the active agent is in slow release form.
  • the dose of the second active agent would be sub-therapeutic if administered without the dose of at least one form of axomadol.
  • the following examples are shown for illustrating the invention related slow release dosage forms comprising at least one form of axomadol and at least one pharmaceutically acceptable excipient, wherein the said dosage form is suitable for once or twice daily oral administration. They also exemplify a dosage form comprising at least one form of axomadol, at least one pharmaceutically acceptable excipient and at least one second active agent, wherein the second active agent is selected from a group consisting of acetaminophen, an NSAID, an Opioid, an antiepileptic, a Norepinephrine Reuptake
  • SNRI Serotonin Norepinephrine reuptake inhibitor
  • COX Cyclo-oxygenase-(COX)-inhibiting nitric oxide donator
  • NMDA N-methyl-D-aspartic acid Receptor antagonist
  • Acetylcholinesterase inhibitor a HT Agonist
  • Proton Pump Inhibitor a Serotonin Norepinephrine reuptake inhibitor
  • the invention discloses a slow release dosage form which can effectively be used in the treatment of pain and pain related diseases wherein the dosage forms comprise a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient.
  • the tablet was prepared as a bilayer tablet as per formula in Table 9;
  • Preparation of Layer 1 Axomadol, microcrystalline cellulose and colloidal silicon dioxide were granulated with polyvinyl alcohol and dried. The dried granules are mixed with Ethylcellulose and Hydroxyethylcellulose and lubricated with Sodium stearyl fumarate.
  • Preparation of Layer 2 Axomadol is mixed with microcrystalline cellulose was granulated with povidone. Granules are dried and mixed with Croscarmellose sodium and finally lubricated with Magnesium stearate.
  • Layer 1 and Layer 2 are loaded into the hopper of bi layer rotary compression machine and compressed with a desired hardness.
  • a slow release dosage form comprising at least one form of axomadol tablets were manufactured as per Table 10;
  • Example 9 The tablets of Example 9, a slow release dosage form comprising at least one form of axomadol tablets, were manufactured in two phases using standard coating processes.
  • phase I the axomadol was formulated into a core.
  • Phase II the above prepared core was further coated with slow release coat to get a slow release axomadol core as per details are given below;
  • Phase I, Core preparation Axomadol is mixed with microcrystalline cellulose and colloidal silicone dioxide and one or mixture of filler and granulated using suitable method known in the art using a binder solution comprising Polyvinylpyrrolidone or polyvinyl alcohol. The granulated axomadol was dried and screened. This is further lubricated using hydrogenated vegetable oil with or without glidant. The lubricated blend is compressed into tablets using a compression machine.
  • Coating Solution and Coating The coating solution is prepared using aqueous dispersion of water insoluble water permeable polymer of Ethylcellulose with water soluble polymer of
  • Polyvinylpyrrolidone or 29 hydroxylpropylmethyl cellulose Polyethylene glycol mixture prepared using propeller stirrer and the same is homogenized using suitable homogenizer.
  • the core tablets are coated using coating solution using standard coater like O' Hara pan coater tip set at 4" at a spray rate of 25 mL/gun/min, exhaust temperature of around 45'C, an atom izat ion pressure from 10-35 psi at a pan speed of 5-8 rpm, using airflow 350 CFM.
  • a slow release dosage form comprising at least one form of axomadol and at least one pharmaceutical excipient were manufactured as per Table 11;
  • Core The slow release axomadol was manufactured by preparing a core and coating with a slow release coat. Core was prepared by granulating 250 mg of axomadol and 167 mg of lactose using a standard granulator. The granulated mix was transferred to a fluid bed granulator and sprayed with 38.75 mg of ethylcellulose and suitable quantity (35 ml) of distilled water. The granules were then dried at 60'C and passed through a 1 mm screen. 103.75 mg of cetostearyl alcohol melt was added to axomadol granules was added and the resulting mixture was mixed thoroughly. The granules were allowed to cool and sieved through a 1.6 mm screen. Purified talc and magnesium stearate were added and mixed with the granules which were then compressed into tablets.
  • Coat The compressed tablets were coated with slow release coating solution prepared according to the Table 13 using standard coating techniques.
  • Examples 11 and 12 of slow release axomadol were prepared according to the manufacturing methods described under Example 10.
  • a different polymer was used in Example 12.
  • the formulations had the composition according to Table 12 and 13;
  • the slow release dosage form particle comprising at least one form of axomadol was prepared by missing equal quantity of axomadol and Hydrogenated Vegetable oil in a mixer at a rotation speed of around 500 RPM. The mechanical action was continued by heating till the contents were fused together and formed into a mass.
  • the slow release seeds were obtained by using a granulator. The granulator sizes dry granulation to the optimum particle size distribution for efficient tabletting. The resulting seeds were subjected warming and mixing for about 5-15 minutes till pre-determined particle sizes are obtained.
  • the resultant particles, alter cooling, are suitably sieved to give particles having a size range from 0.1 to 3.0 mm, preferably 0.25 to 2.0 mm. The resulting particles may be sieved to form the desired dosage units.
  • the resulting particles may be further mixed with Ethyl Cellulose and Cetostearyl alcohol and compressed into tablets.
  • the compressed tablets were coated with coating solution prepared according to the formula in Table 17.
  • the slow release composition comprising at least one form of axomadol, additional Examples of 16 -18, were manufactured using the same manufacturing method as described for Examples 13-15.
  • the composition consisted of the formula in Table 17 below;
  • a delayed release tablet comprising 50 mg, 100 mg and 150 mg immediate release axomadol tablets was prepared as per the formula in Table 18 using standard manufacturing methods reported in the art.
  • the axomadol is delumped by passing it through a 40 mesh screen and collecting it in a clean, polyethylene-lined container and was granulated with Polyvinyl Alcohol and Colloidal Silicon Dioxide in a granulator. The granulated mix was mixed with D-mannitol and sodium stearyl fumarate in a blender. The blended granulated axomadol mix was compressed into tablets. The cellulose acetate, hydroxypropyl cellulose was dissolved in organic solvents and mixed with sodium chloride. The compressed axomadol tablets were coated using standard coating techniques.
  • Yet another slow release dosage form comprising at least one form axomadol was prepared using multiparticulate osmotic technology using CEFORM according to the formula in Table 20.
  • Example 20 The dosage form of Example 20 was prepared using Ceform microsphere technology (Fuisz Technology Ltd., USA). This technology allows the production of uniformly sized and shaped microspheres of pharmaceutical compounds. These microspheres are almost perfectly spherical, having a diameter that is typically 150 to 180 mm, and allow for high drug content. The microspheres can be used in a wide variety of dosage forms, including tablets, capsules, suspensions, effervescent tablets, and sachets.
  • the microspheres can be formulated for enhanced absorption (Ceform EA) or taste isolation (Ceform TI) and may be coated for controlled release (Ceform CR), provided with an enteric coating (Ceform EC), or combined into a fast/slow release combination (Ceform EA/CR).
  • the microspheres comprising axomadol was coated with a slow release coating release solution prepared using Ethyl Cellulose, Hydroxypropyl cellulose, micronized talc in acetone/I-propyl alcohol solvents.
  • Example 21 prepared according to Table 21 using a lipid hydrophobic system is yet another slow release axomadol dosage form.
  • Axomadol, hydroxypropyl cellulose, and hydrogenated vegetable oil are agglomerated by means of a molten binder and processed into spherical or nearly spherical granules of homogeneous size using melt granulation at about 85-90'C process.
  • the homogenized mix was solidified, screened in a suitable screener, milled and sized.
  • the lubricant was added and tablets were compressed.
  • the osmotic coating solution comprising Opadry solution was used to coat the compressed axomadol tablets in a coater.
  • Example 22 prepared according to Table 22 using a wax hydrophobic system is yet another slow release axomadol dosage form.
  • Examples 23-32 prepared according to the formulas in Tables 23 to 34 are a set of other slow release axomadol dosage examples for illustrative purposes. Without further description, it is believed that one of ordinary skill in the art can, using the preceding description and the following illustrative examples, make and utilize the disclosed compositions. The following working examples therefore, are provided for the purpose of illustration only and specifically point out the preferred embodiments, and are not to be construed as limiting in any way the remainder of the disclosure. Therefore, the examples should be construed to encompass any and all variations which become evident as a result of the teaching provided herein. EXAMPLE 23;
  • Axomadol Beads 66 Axomadol Granules 33
  • This Example discloses a pharmaceutical composition which can effectively be used in the treatment of pain and pain related diseases wherein the compositions comprise a therapeutically effective amount of axomadol and at least one pharmaceutically acceptable excipient and Sumatriptan Succinate
  • the tablet was prepared as per formula in Table 35;
  • MANUFACTURING PROCESS [00173] Preparation of Layer 1 : Sumatriptan Succinate, microcrystalline cellulose and colloidal silicon dioxide were granulated with polyvinyl alcohol and dried. The dried granules are mixed with Ethyl
  • Magnesium stearate Magnesium stearate.
  • Axomadol was coated over the coated tablets cores using standard manufacturing process known in the art. Table 38
  • Example 38-42 of this invention disclose a pharmaceutical composition which can effectively be used in the treatment of pain and pain related diseases wherein the compositions comprise a
  • Axomadol and at least one pharmaceutically acceptable excipient and either Pregabalin or Gabapentin or Famotidine or Pentaprazole or Esomeprazole or Omeprazole according the formulas disclosed in the Tables 39-44. These combinations can be manufacturing according standard manufacturing methods known in art.
  • EXAMPLE 38 AXOMADOL-PREGABALBV COMBINATION
  • EXAMPLE 38 B AXOMADOL-PREGABALEV COMBINATION
  • the slow -release tablet comprising Axomadol and Pregabalin is prepared using a three step process: 1) Granulation, 2) Tabletting and 3) Membrane coating process. An optional Seal Coating may be done on the core tablet. These are described below [00180] Granulation: The Povidone, K-30, and sodium tribasic phosphate are dissolved in purified water. Axomadol is collected in a clean, polyethylene-lined container after it is delumped by passing it through a 40 mesh screen.
  • the delumped Axomadol is then added to a top-spray fluidized bed granulator and granulated by spraying the binding solution of Povidone and sodium tribasic phosphate at an inlet air temperature of 50-70' C, an atom izat ion air pressure of 1-3 bars and a spray rate of 10-100 ml/min.
  • the binding solution is depleted, the granules are dried in the granulator until the loss on drying is less than 2% and are passed through a comil equipped with the equivalent of an 18 mesh screen.
  • the granules are compressed on a rotary press fitted with ⁇ fraction (15/32)" round standard concave punches.
  • the orifice may be formed by any means commonly employed in the pharmaceutical industry.
  • the seal coating of the tablet can be done by first dissolving the Opadry material, preferably Opadry Clear, in purified water and spraying the Opadry solution onto the core tablet using a pan coater at an exhaust air temperature of 38-42' C degree, an atomization pressure of 28-40 psi and a spay rate of 10-15 ml/min.
  • the core tablet is coated with the sealing solution until a theoretical coating level of approximately 2-4% is obtained.
  • Membrane Coating Process A homogenizer was used for dissolving the cellulose acetate is dissolved in acetone. The polyethylene glycol 400 and triacetin are added to the cellulose acetate solution and stirred until a clear solution is obtained. The clear membrane coating solution is then sprayed onto the seal coated tablets using a fluidized bed coater employing the following conditions: product temperature of 16-22'C, atomization pressure of approximately 3 bars and spray rate of 120-150 ml/min. The sealed core tablet is coated until a theoretical coating level of approximately 3% is obtained. Tween 80 and hydroxypropyl methylcellulose are dissolved in purified water. Pregabalin is then dispersed into this solution. The resulting suspension is then sprayed onto the above-membrane-coated tablets.
  • the invention discloses a slow release dosage form which can effectively be used in the treatment of pain and pain related diseases wherein the dosage forms comprise a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient and at least one form of naproxcinod.
  • the tablet was prepared as exemplified in Table 44;
  • Preparation of Layer 1 Axomadol, microcrystalline cellulose and colloidal silicon dioxide were granulated with polyvinyl alcohol and dried. The dried granules are mixed with Ethylcellulose and
  • Magnesium stearate Magnesium stearate.
  • Layer 1 and Layer 2 are loaded into the hopper of bilayer rotary compression machine and compressed into a tablet comprising axomadol and naproxcinod with a desired hardness.
  • the invention discloses a slow release dosage form which can effectively be used in the treatment of pain and pain related diseases wherein the dosage forms comprise a therapeutically effective amount of at least one form of axomadol and at least one pharmaceutically acceptable excipient and at least one form of naproxen.
  • the tablet was prepared as exemplified in Table 45 and was manufactured according to the process described for Example 43;
  • the tablet was prepared as exemplified in Table 46 and was manufactured according to the process described for Example 43;
  • composition of instant invention exhibits an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37.degree. C.) such that after 2 hours, from about 0% up to about 30% (by weight) of axomadol is released, after 4 hours, from about 5% to about 55% (by weight) of axomadol is released, after 12 hours, more than about 50% (by weight) of axomadol is released, and after 24 hours, more than about 80% (by weight) of axomadol is released.
  • composition of instant invention exhibits an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37' C.) such that after 2 hours, from about 0% up to about 30% (by weight) of axomadol is released, after 4 hours, from about 5% to about 22% (by weight) of axomadol is released, after 6 hours, from about 15% to about 38% (by weight) of the axomadol is released, after 8 hours, more than about 40% (by weight) of axomadol is released.
  • an in vitro dissolution profile measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37' C.
  • composition of instant invention exhibits an in vitro dissolution profile (measured using the USP Basket Method at 75 rpm in 900 ml 0.1 N HCl at 37' C.) such that after 2 hours, from about 2% to about 10% of axomadol is released, after 4 hours, from about 12% to about 20% of axomadol is released, after 6 hours, from about 30% to about 38% of axomadol is released, after 8 hours, from about 48% to about 56% of axomadol is released, after 10 hours, from about 64% to about 72% of axomadol is released, and after 12 hours, more than about 76% of axomadol is released.
  • Table 49 provides the dissolution data of the three Examples 1, 2 and 3;
  • FIGURE 2 is the dissolution profile of a slow release Axomadol dosage form according to Examples 6.
  • Example 10-12 The dissolution studies of Example 10-12 were carried out using Ph. Eur. Paddle Method 100 rpm, in 900 ml 0.1 N hydrochloric acid at 37'C. and using UV detection at 270 nm and the in vitro dissolution of axomadol are in Table 51;
  • the in vitro release rate preferably corresponds to the following rate of axomadol released; between 0 and 50% axomadol released after 1 hour; between 0 and 75% axomadol released after 2 hours; between 3 and 95% axomadol released after 4 hours; between 10 and 100% axomadol released after 8 hours; between 20 and 100% axomadol released after 12 hours; between 30 and 100% axomadol released after 16 hours; between 50 and 100% axomadol released after 24 hours; and greater than 80% axomadol released after 36 hours, by weight.
  • Another preferred preparation especially suited for twice-a-day dosing has an in vitro release rate corresponding to the following % rate of axomadol released: between 20 and 50% axomadol released after 1 hour; between 40 and 75% axomadol released after 2 hours; between 60 and 95% axomadol released after 4 hours; between 80 and 100% axomadol released after 8 hours; between 90 and 100% axomadol released after 12 hours; by weight
  • Yet another preferred preparation particularly suited for once-a-day dosing has an in-vitro release rate corresponding to the following % rate of axomadol released:
  • a still further preferred preparation in accordance with the invention also particularly suited for once-a-day dosing has an in vitro release rate corresponding to the following % rate if; between 0 and
  • a preparation for once-a-day dosing has an in vitro release rate substantially as follows: between 15 and 25% axomadol released after 1 hour; between 25 and 35% axomadol released after 2 hours; between 30 and 45% axomadol released after 4 hours; between 40 and 60% axomadol released after 8 hours; between 55 and 70% axomadol released after 12 hours; between 60 and 75% axomadol released after 16 hours; by weight.
  • the release profile can be modified in a number of ways; 1 ) loading of the drug will be associated with increased release rates; 2) the use of larger proportions of the water soluble fusible material in the particles or surface active agent in the tabletting formulation will also be associated with a higher release rate of the active ingredient and, 3) by controlling the relative amounts of these ingredients it is possible to adjust the release profile of the axomadol or a salt thereof.
  • Examples 13-18 were prepared by preparing different particle sizes and they were subjected to in vitro dissolution test using Ph. Eur. Paddle Method 100 rpm, in 900 ml 0.1 N hydrochloric acid at 37'C, using UV detection at 270 nm. The results are in Tables 53 and 54.
  • the Reference Example 1 at least one form of axomadol was evaluated for dissolution profile using a method as per U.S. Pharmacopoeia XXII Paddle Method in phosphate buffer at pH7.4 and at 50 rpm, the dissolution rate for the final tablets was as follows in Table 55
  • the present inventions further include a method of treating pain and pain related conditions. This was established using four well controlled human clinical trials for one slow release Axomadol dosage form (Example 10) and three different combinations Examples 36, 38 and 43. A typical study determined the efficacy of either a slow release dosage form of Axomadol compared to that of an Immediate Release dosage form (Reference Example 2) or that of a combination in comparison with monotherapy with respective drugs.
  • the fixed dose combination comprising Axomadol and Sumatriptan (Example 36), a combination comprising Axomadol and Pregabalin (Example 38), a combination comprising Axomadol and Naproxen (Example 44). Each of these combinations was compared against monotherapy with the respective drugs for the treatment of pain and pain related conditions in patients.
  • Intervention Model Parallel Assignment
  • VAS baseline pain intensity
  • Arm 1 Active Comparator- Axomadol 100 mg tablet (Example 10) by mouth followed by
  • Arm 2 Active Comparator- Axomadol 100 mg tablet (Reference Example 2) by mouth followed by an Axomadol 100 mg tablet (Reference Example 2) by mouth after 1 to 12 hours of the initial dose on
  • Eligible subjects included type 1 and type 2 diabetic patients not on any other medications for their neuropathic pain and with stable diabetic control. Exclusion criteria included erratic glycemic control, peripheral vascular disease (PVD) with absent foot pulses, presence of active foot ulceration, treatment with sublingual glyceryl trinitrate, patients on erectile dysfunction drugs, factors affecting the patient's evaluation of pain, and the presence of other causes of peripheral neuropathies. No major changes made for diabetes treatment during the duration of the study.
  • PVD peripheral vascular disease
  • Axomadol 250 mg or pregabalin 250 mg or Axomadol 250 mg + pregabalin 250 mg FDC for 4 weeks.
  • a 10-cm visual analog scale (VAS) was recorded biweekly by the patients for pain, where 0 means no pain at all and 10 means the most severe pain ever experienced.
  • the treatment effect was defined to be the difference between the final score and the baseline score on the Likert scale for each treatment phase.
  • the objectives of the inventions are met for the fixed dose combination comprising axomadol and pregabalin produced statistically significant and clinically meaningful reductions, compared to the monotherapy using either axomadol or pregabalin, for the primary efficacy variable in pain intensity associated with diabetic neuropathy.
  • a clinically significant benefit of using fixed dose axomadol and pregabalin/gabapentin would be a reduction in the pain score (VAS) of at least 15 % compared to the other treatment.
  • An adult female migraineur complains of a migraine attack with typical symptoms: headache, nausea and sensitivity to light and sound. She is administered a single oral tablet containing Example 35; Fixed Dose Combination of Axomadol (50 mg) and Sumatriptan (50 mg) Combination. Her symptoms start to diminish within one hour and, by three hours, she is completely symptom free. No relapse over the next 48 hours is reported.
  • Example 35 An adult female migraineur complains of a migraine attack with typical symptoms: migraine headache, nausea and sensitivity to light and sound. She is administered a single oral tablet containing Example 35; Fixed Dose Combination of Axomadol (50 mg) and Sumatriptan (50 mg). Her symptoms start to diminish within one hour. By three hours, she is completely symptom free and has no relapse over the next 48 hours.
  • Treatment Arms [00241] Treatment A; Fixed Dose Combination of Axomadol 50 mg +Naproxen 250 mg (Example 44,
  • Treatment B Axomadol 50 mg (Reference Example 1, Comparator)
  • Treatment C Naproxen 250 mg
  • CNCP Chronic non-cancer pain
  • Randomization was performed with computer-generated random numbers in blocks of 10.
  • Randomization codes of the Study Drug or Comparator treatments were placed in sequentially numbered, opaque, sealed envelopes in the biopsy center. When a patient was recruited and consented, the next numbered envelope was opened by the operator, who had no knowledge of the randomization code before the treatment.
  • VAS visual analogue scale

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne une forme pharmaceutique à libération lente comprenant une quantité thérapeutiquement efficace d’au moins une forme d’axomadol, au moins un excipient pharmaceutiquement acceptable, ladite forme pharmaceutique étant conçue pour être administrée une à deux fois par jour. Cette invention concerne également une méthode de traitement d’un mammifère consistant à administrer ces formes pharmaceutiques à libération lente. L’invention concerne également une forme pharmaceutique comprenant une quantité thérapeutiquement efficace d’au moins une forme d’axomadol, au moins un excipient pharmaceutiquement acceptable et au moins un second agent actif, ledit second agent actif étant choisi dans le groupe constitué par l’acétaminophène, un NSADD, un opioïde, un antiépileptique, un inhibiteur de la recapture de la norépinephrine, un inhibiteur de la recapture de la sérotonine, un donneur d’oxyde nitrique inhibiteur de la cyclo-oxygénase, un antagoniste du récepteur NMDA (acide N-méthyl-D-aspartique), un inhibiteur de l’acétylcholinestérase, un agoniste HT et un inhibiteur de la pompe à protons, et une méthode de traitement de l’homme consistant à administrer ces formes pharmaceutiques associant l’axomadol et au moins un second agent actif.
PCT/US2010/002011 2009-07-16 2010-07-16 Nouvelles formes pharmaceutiques de l’axomadol WO2011008298A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27098609P 2009-07-16 2009-07-16
US61/270,986 2009-07-16

Publications (2)

Publication Number Publication Date
WO2011008298A2 true WO2011008298A2 (fr) 2011-01-20
WO2011008298A3 WO2011008298A3 (fr) 2011-06-16

Family

ID=43450043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2010/002011 WO2011008298A2 (fr) 2009-07-16 2010-07-16 Nouvelles formes pharmaceutiques de l’axomadol

Country Status (1)

Country Link
WO (1) WO2011008298A2 (fr)

Cited By (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012003968A1 (fr) * 2010-07-06 2012-01-12 Grünenthal GmbH Nouvelles formes posologiques à rétention gastrique comprenant un analogue de gaba et un opioïde
CN102670544A (zh) * 2012-06-05 2012-09-19 石家庄四药有限公司 一种拉科酰胺缓释片及其制备方法
CN102885796A (zh) * 2012-07-30 2013-01-23 永光制药有限公司 一种治疗癫痫的拉科酰胺片剂及其制备方法
WO2013119794A1 (fr) * 2012-02-08 2013-08-15 Supernus Pharmaceuticals, Inc. Formulations à libération modifiée de viloxazine
CN103432107A (zh) * 2013-08-20 2013-12-11 安徽省先锋制药有限公司 一种盐酸他喷他多对乙酰氨基酚口腔崩解片及其制备方法
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
EP2886116A1 (fr) * 2013-12-18 2015-06-24 Biocodex Dérivés du benzodioxol pour leur utilisation dans le traitement du trouble du déficit de l'attention et/ou de l'hyperactivité
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN105228608A (zh) * 2013-04-02 2016-01-06 比奥生物有限公司 容易调节拉科酰胺或其药学上可允许的盐的溶出模式的药学组合物
CN105412047A (zh) * 2015-12-03 2016-03-23 烟台东诚药业集团股份有限公司 一种骨架型盐酸美金刚缓释胶囊及其制备方法
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
CN109692168A (zh) * 2017-10-23 2019-04-30 重庆润泽医药有限公司 治疗老年痴呆的药物组合物及其制备方法
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US11324753B2 (en) 2008-09-05 2022-05-10 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
KR20230076278A (ko) * 2021-11-24 2023-05-31 부산대학교 산학협력단 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물
WO2023096258A1 (fr) * 2021-11-24 2023-06-01 부산대학교 산학협력단 Composition pour la prévention ou le traitement d'une maladie intestinale inflammatoire, comprenant du riluzole ou un nouveau dérivé du riluzole comme principe actif
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form
KR20240025777A (ko) * 2022-08-19 2024-02-27 부산대학교 산학협력단 리루졸 유도체 및 이를 유효성분으로 포함하는 대장 표적성 염증성 장질환 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
US20060121113A1 (en) * 2003-07-24 2006-06-08 Gruenenthal Gmbh Pharmaceutical composition containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
US20080306161A1 (en) * 2007-05-11 2008-12-11 Gruenenthal Gmbh Use of Axomadol for Treatment of Arthrosis Pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176790A1 (en) * 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
US20060121113A1 (en) * 2003-07-24 2006-06-08 Gruenenthal Gmbh Pharmaceutical composition containing 6-dimethylaminomethyl-1-(3-methoxyphenyl)-cyclohexane-1,3-diol with delayed active ingredient release
US20080306161A1 (en) * 2007-05-11 2008-12-11 Gruenenthal Gmbh Use of Axomadol for Treatment of Arthrosis Pain

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIWARI, S. B. ET AL.: 'Controlled Release Formulation of Tramadol Hydrochloride Using Hydrophilic and Hydrophobic Matrix System' AAPS PHARMSCITECH vol. 4, no. 3, 2003, *

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10369109B2 (en) 2002-06-17 2019-08-06 Grünenthal GmbH Abuse-proofed dosage form
US9675610B2 (en) 2002-06-17 2017-06-13 Grünenthal GmbH Abuse-proofed dosage form
US9629807B2 (en) 2003-08-06 2017-04-25 Grünenthal GmbH Abuse-proofed dosage form
US10058548B2 (en) 2003-08-06 2018-08-28 Grünenthal GmbH Abuse-proofed dosage form
US10130591B2 (en) 2003-08-06 2018-11-20 Grünenthal GmbH Abuse-proofed dosage form
US11224576B2 (en) 2003-12-24 2022-01-18 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US11844865B2 (en) 2004-07-01 2023-12-19 Grünenthal GmbH Abuse-proofed oral dosage form
US10729658B2 (en) 2005-02-04 2020-08-04 Grünenthal GmbH Process for the production of an abuse-proofed dosage form
US10675278B2 (en) 2005-02-04 2020-06-09 Grünenthal GmbH Crush resistant delayed-release dosage forms
US9750701B2 (en) 2008-01-25 2017-09-05 Grünenthal GmbH Pharmaceutical dosage form
US12121523B2 (en) 2008-09-05 2024-10-22 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
US11458143B2 (en) 2008-09-05 2022-10-04 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
US11324753B2 (en) 2008-09-05 2022-05-10 Supernus Pharmaceuticals, Inc. Method of treatment of attention deficit/hyperactivity disorder (ADHD)
US10493033B2 (en) 2009-07-22 2019-12-03 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US9925146B2 (en) 2009-07-22 2018-03-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
US10080721B2 (en) 2009-07-22 2018-09-25 Gruenenthal Gmbh Hot-melt extruded pharmaceutical dosage form
AU2016203567B2 (en) * 2010-07-06 2017-12-07 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
AU2011276170B2 (en) * 2010-07-06 2016-03-10 Grunenthal Gmbh Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
WO2012003968A1 (fr) * 2010-07-06 2012-01-12 Grünenthal GmbH Nouvelles formes posologiques à rétention gastrique comprenant un analogue de gaba et un opioïde
US10300141B2 (en) 2010-09-02 2019-05-28 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
US9636303B2 (en) 2010-09-02 2017-05-02 Gruenenthal Gmbh Tamper resistant dosage form comprising an anionic polymer
US10201502B2 (en) 2011-07-29 2019-02-12 Gruenenthal Gmbh Tamper-resistant tablet providing immediate drug release
US10695297B2 (en) 2011-07-29 2020-06-30 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US10864164B2 (en) 2011-07-29 2020-12-15 Grünenthal GmbH Tamper-resistant tablet providing immediate drug release
US9603853B2 (en) 2012-02-08 2017-03-28 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
US20190201407A1 (en) * 2012-02-08 2019-07-04 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
US10265319B2 (en) 2012-02-08 2019-04-23 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
AU2017206245B2 (en) * 2012-02-08 2019-05-16 Supernus Pharmaceuticals, Inc. Modified release formulations of viloxazine
EP4233915A3 (fr) * 2012-02-08 2023-09-20 Supernus Pharmaceuticals, Inc. Formulations de liberation modifiée du viloxazine
WO2013119794A1 (fr) * 2012-02-08 2013-08-15 Supernus Pharmaceuticals, Inc. Formulations à libération modifiée de viloxazine
US9662338B2 (en) 2012-02-08 2017-05-30 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
US9358204B2 (en) 2012-02-08 2016-06-07 Supernus Pharmaceuticals, Inc. Formulations of viloxazine
US9655853B2 (en) 2012-02-28 2017-05-23 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
US10335373B2 (en) 2012-04-18 2019-07-02 Grunenthal Gmbh Tamper resistant and dose-dumping resistant pharmaceutical dosage form
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
CN102670544B (zh) * 2012-06-05 2016-04-06 石家庄四药有限公司 一种拉科酰胺缓释片及其制备方法
CN102670544A (zh) * 2012-06-05 2012-09-19 石家庄四药有限公司 一种拉科酰胺缓释片及其制备方法
CN102885796A (zh) * 2012-07-30 2013-01-23 永光制药有限公司 一种治疗癫痫的拉科酰胺片剂及其制备方法
US8889190B2 (en) 2013-03-13 2014-11-18 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US10363224B2 (en) 2013-03-13 2019-07-30 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
US9555005B2 (en) 2013-03-15 2017-01-31 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
US10172878B2 (en) 2013-03-15 2019-01-08 Upsher-Smith Laboratories, Llc Extended-release topiramate capsules
CN105228608A (zh) * 2013-04-02 2016-01-06 比奥生物有限公司 容易调节拉科酰胺或其药学上可允许的盐的溶出模式的药学组合物
CN105228608B (zh) * 2013-04-02 2019-05-28 比奥生物有限公司 容易调节拉科酰胺或其药学上可允许的盐的溶出模式的药学组合物
US10154966B2 (en) 2013-05-29 2018-12-18 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
US9737490B2 (en) 2013-05-29 2017-08-22 Grünenthal GmbH Tamper resistant dosage form with bimodal release profile
US10624862B2 (en) 2013-07-12 2020-04-21 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
US10639281B2 (en) 2013-08-12 2020-05-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US10195153B2 (en) 2013-08-12 2019-02-05 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
CN103432107A (zh) * 2013-08-20 2013-12-11 安徽省先锋制药有限公司 一种盐酸他喷他多对乙酰氨基酚口腔崩解片及其制备方法
US10449547B2 (en) 2013-11-26 2019-10-22 Grünenthal GmbH Preparation of a powdery pharmaceutical composition by means of cryo-milling
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10792254B2 (en) 2013-12-17 2020-10-06 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP2886116A1 (fr) * 2013-12-18 2015-06-24 Biocodex Dérivés du benzodioxol pour leur utilisation dans le traitement du trouble du déficit de l'attention et/ou de l'hyperactivité
WO2015091718A1 (fr) * 2013-12-18 2015-06-25 Biocodex Dérivés de benzodioxol pour une utilisation dans le traitement de déficit de l'attention et/ou de l'hyperactivité
US9913814B2 (en) 2014-05-12 2018-03-13 Grünenthal GmbH Tamper resistant immediate release capsule formulation comprising tapentadol
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US10959958B2 (en) 2014-10-20 2021-03-30 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
US9855263B2 (en) 2015-04-24 2018-01-02 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
US10842750B2 (en) 2015-09-10 2020-11-24 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
CN105412047A (zh) * 2015-12-03 2016-03-23 烟台东诚药业集团股份有限公司 一种骨架型盐酸美金刚缓释胶囊及其制备方法
CN109692168A (zh) * 2017-10-23 2019-04-30 重庆润泽医药有限公司 治疗老年痴呆的药物组合物及其制备方法
WO2023096258A1 (fr) * 2021-11-24 2023-06-01 부산대학교 산학협력단 Composition pour la prévention ou le traitement d'une maladie intestinale inflammatoire, comprenant du riluzole ou un nouveau dérivé du riluzole comme principe actif
KR20230076278A (ko) * 2021-11-24 2023-05-31 부산대학교 산학협력단 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물
KR102625977B1 (ko) 2021-11-24 2024-01-17 부산대학교 산학협력단 리루졸을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 조성물
KR20240025777A (ko) * 2022-08-19 2024-02-27 부산대학교 산학협력단 리루졸 유도체 및 이를 유효성분으로 포함하는 대장 표적성 염증성 장질환 예방 또는 치료용 조성물
KR102785404B1 (ko) 2022-08-19 2025-03-21 부산대학교 산학협력단 리루졸 유도체 및 이를 유효성분으로 포함하는 대장 표적성 염증성 장질환 예방 또는 치료용 조성물

Also Published As

Publication number Publication date
WO2011008298A3 (fr) 2011-06-16

Similar Documents

Publication Publication Date Title
WO2011008298A2 (fr) Nouvelles formes pharmaceutiques de l’axomadol
AU2015271879B2 (en) Novel and potent tapentadol dosage forms
KR101752014B1 (ko) 고용량 및 저용량 약물들의 조합을 포함하는 구강붕해정 조성물
CN105534936B (zh) 抗滥用药物、使用方法和制备方法
DK2596784T3 (en) Tapentadol compositions
AU2016203567B2 (en) Novel gastro- retentive dosage forms comprising a GABA Analog and an opioid
US20120015031A1 (en) Novel gastro-retentive dosage forms
WO2010141505A1 (fr) Systèmes d'administration résistants aux abus
JP2004515455A (ja) オピオイドアンタゴニスト組成物および投薬形態
CN106456550A (zh) 避免乙醇剂量倾泻的多颗粒
US20080031950A1 (en) Novel anelgesic combination
US20080014261A1 (en) Non-narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction
US20080008772A1 (en) Narcotic biphasic release compositions and methods for treatment of coughing, sneezing, rhinorrhea, and/or nasal obstruction

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10800171

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10800171

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载